Pasithea Therapeutics annual depreciation and amortization
2021
2022
2023
2024
2025
Pasithea Therapeutics Depreciation & Amortization Growth & History (KTTA)
Pasithea Therapeutics's depreciation and amortization was $32,421 for fiscal 2025.
View full Pasithea Therapeutics company overviewPasithea Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $32,421 | $13,556 | +71.86% |
| 2024 | 2024-12-31 | $18,865 | $575 | +3.14% |
| 2023 | 2023-12-31 | $18,290 | $13,196 | +259.05% |
| 2022 | 2022-12-31 | $5,094 | $3,715 | +269.40% |
| 2021 | 2021-12-31 | $1,379 | — | — |
Pasithea Therapeutics quarterly depreciation and amortization
Q1.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $157,541 | $153,541 | +3838.53% |
| Q1 2026 | 2026-03-31 | $157,541 | $152,720 | +3167.81% |
| Q4 2025 | 2025-12-31 | $157,541 | — | — |
| Q3 2025 | 2025-09-30 | $24,000 | $19,000 | +380.00% |
| Q2 2025 | 2025-06-30 | $4,000 | −$1,000 | −20.00% |
| Q1 2025 | 2025-03-31 | $4,821 | $104 | +2.20% |
| Q3 2024 | 2024-09-30 | $5,000 | $285 | +6.04% |
| Q2 2024 | 2024-06-30 | $5,000 | $284 | +6.02% |
| Q1 2024 | 2024-03-31 | $4,717 | $538 | +12.87% |
| Q3 2023 | 2023-09-30 | $4,715 | — | — |
| Q2 2023 | 2023-06-30 | $4,716 | — | — |
| Q1 2023 | 2023-03-31 | $4,179 | −$835 | −16.65% |
| Q1 2022 | 2022-03-31 | $5,014 | — | — |
Pasithea Therapeutics depreciation and amortization trends
Between the periods ended 2021-12-31 and 2025-12-31, Pasithea Therapeutics's depreciation and amortization increased from $1,379 to $32,421, a change of $31,042. The latest reported quarter, Q2 2026, shows $157,541.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pasithea Therapeutics source filings ↗